APO Research
Talk to an analyst

APO RESEARCH · REPORT

Toxoid Vaccines

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Toxoid Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

22 December 2025196 pages

Choose your research edition.

Industry ResearchToxoid Vaccines Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Toxoid Vaccines Industry Growth and Trends Forecast to 2032105 pages · $3,450 USDMarket StructureGlobal Toxoid Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Toxoid Vaccines Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Toxoid Vaccines Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Toxoid Vaccines market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Toxoid Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Toxoid Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Toxoid Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Toxoid Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Toxoid Vaccines include Shenzhen Kangtai Biological Products, Merck, Pfizer, GlaxoSmithKline, AstraZeneca, Sanofi Pasteur, Panacea Biotec, Emergent Biosolutions and Bharat Biotech, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Toxoid Vaccines market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Toxoid Vaccines and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Toxoid Vaccines sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Toxoid Vaccines market size, projected growth trends, production technologies, key applications, and end-use industries.

Toxoid Vaccines Segment by Company

Shenzhen Kangtai Biological Products

Merck

Pfizer

GlaxoSmithKline

AstraZeneca

Sanofi Pasteur

Panacea Biotec

Emergent Biosolutions

Bharat Biotech

Bausch Health

Astellas Pharma

Toxoid Vaccines Segment by Type

Tetanus

Monovalent Tetanus Toxoid (TT)

Pertussis (DTaP)

Diphtheria and Tetanus (DT)

Diphtheria

Toxoid Vaccines Segment by Application

Government Organizations

Hospitals And Clinics

Research

Others

Toxoid Vaccines Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Toxoid Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Toxoid Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Toxoid Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Toxoid Vaccines market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Toxoid Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Toxoid Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Toxoid Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Toxoid Vaccines Industry Trends Table 2. Toxoid Vaccines Industry Drivers Table 3. Toxoid Vaccines Industry Opportunities and Challenges Table 4. Toxoid Vaccines Industry Restraints Table 5. Global Toxoid Vaccines Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Toxoid Vaccines Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Toxoid Vaccines Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Toxoid Vaccines Sales Market Share by Manufacturers Table 9. Global Toxoid Vaccines Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Toxoid Vaccines Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Toxoid Vaccines Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Toxoid Vaccines Manufacturers, Product Type & Application Table 13. Global Toxoid Vaccines Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Toxoid Vaccines by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Tetanus Table 17. Major Manufacturers of Monovalent Tetanus Toxoid (TT) Table 18. Major Manufacturers of Pertussis (DTaP) Table 19. Major Manufacturers of Diphtheria and Tetanus (DT) Table 20. Major Manufacturers of Diphtheria Table 21. Global Toxoid Vaccines Sales by Type 2021 VS 2025 VS 2032 (k units) Table 22. Global Toxoid Vaccines Sales by Type (2021-2026) & (k units) Table 23. Global Toxoid Vaccines Sales by Type (2027-2032) & (k units) Table 24. Global Toxoid Vaccines Sales Market Share by Type (2021-2026) Table 25. Global Toxoid Vaccines Sales Market Share by Type (2027-2032) Table 26. Global Toxoid Vaccines Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 27. Global Toxoid Vaccines Revenue by Type (2021-2026) & (k units) Table 28. Global Toxoid Vaccines Revenue by Type (2027-2032) & (k units) Table 29. Global Toxoid Vaccines Revenue Market Share by Type (2021-2026) Table 30. Global Toxoid Vaccines Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Government Organizations Table 32. Major Manufacturers of Hospitals And Clinics Table 33. Major Manufacturers of Research Table 34. Major Manufacturers of Others Table 35. Global Toxoid Vaccines Sales by Application 2021 VS 2025 VS 2032 (k units) Table 36. Global Toxoid Vaccines Sales by Application (2021-2026) & (k units) Table 37. Global Toxoid Vaccines Sales by Application (2027-2032) & (k units) Table 38. Global Toxoid Vaccines Sales Market Share by Application (2021-2026) Table 39. Global Toxoid Vaccines Sales Market Share by Application (2027-2032) Table 40. Global Toxoid Vaccines Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 41. Global Toxoid Vaccines Revenue by Application (2021-2026) & (k units) Table 42. Global Toxoid Vaccines Revenue by Application (2027-2032) & (k units) Table 43. Global Toxoid Vaccines Revenue Market Share by Application (2021-2026) Table 44. Global Toxoid Vaccines Revenue Market Share by Application (2027-2032) Table 45. Global Toxoid Vaccines Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 46. Global Toxoid Vaccines Sales by Region (2021-2026) & (k units) Table 47. Global Toxoid Vaccines Sales Market Share by Region (2021-2026) Table 48. Global Toxoid Vaccines Sales Forecasted by Region (2027-2032) & (k units) Table 49. Global Toxoid Vaccines Sales Forecasted Market Share by Region (2027-2032) Table 50. North America Toxoid Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 51. North America Toxoid Vaccines Sales by Country (2021-2026) & (k units) Table 52. North America Toxoid Vaccines Sales by Country (2027-2032) & (k units) Table 53. Europe Toxoid Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 54. Europe Toxoid Vaccines Sales by Country (2021-2026) & (k units) Table 55. Europe Toxoid Vaccines Sales by Country (2027-2032) & (k units) Table 56. Asia Pacific Toxoid Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 57. Asia Pacific Toxoid Vaccines Sales by Country (2021-2026) & (k units) Table 58. Asia Pacific Toxoid Vaccines Sales by Country (2027-2032) & (k units) Table 59. South America, Middle East and Africa Toxoid Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 60. South America, Middle East and Africa Toxoid Vaccines Sales by Country (2021-2026) & (k units) Table 61. South America, Middle East and Africa Toxoid Vaccines Sales by Country (2027-2032) & (k units) Table 62. Global Toxoid Vaccines Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 63. Global Toxoid Vaccines Revenue by Region (2021-2026) & (US$ Million) Table 64. Global Toxoid Vaccines Revenue by Region (2027-2032) & (US$ Million) Table 65. Global Toxoid Vaccines Revenue Market Share by Region (2021-2026) Table 66. Global Toxoid Vaccines Revenue Market Share by Region (2027-2032) Table 67. Shenzhen Kangtai Biological Products Company Information Table 68. Shenzhen Kangtai Biological Products Business Overview Table 69. Shenzhen Kangtai Biological Products Toxoid Vaccines Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Shenzhen Kangtai Biological Products Toxoid Vaccines Product Portfolio Table 71. Shenzhen Kangtai Biological Products Recent Development Table 72. Merck Company Information Table 73. Merck Business Overview Table 74. Merck Toxoid Vaccines Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Merck Toxoid Vaccines Product Portfolio Table 76. Merck Recent Development Table 77. Pfizer Company Information Table 78. Pfizer Business Overview Table 79. Pfizer Toxoid Vaccines Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Pfizer Toxoid Vaccines Product Portfolio Table 81. Pfizer Recent Development Table 82. GlaxoSmithKline Company Information Table 83. GlaxoSmithKline Business Overview Table 84. GlaxoSmithKline Toxoid Vaccines Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. GlaxoSmithKline Toxoid Vaccines Product Portfolio Table 86. GlaxoSmithKline Recent Development Table 87. AstraZeneca Company Information Table 88. AstraZeneca Business Overview Table 89. AstraZeneca Toxoid Vaccines Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. AstraZeneca Toxoid Vaccines Product Portfolio Table 91. AstraZeneca Recent Development Table 92. Sanofi Pasteur Company Information Table 93. Sanofi Pasteur Business Overview Table 94. Sanofi Pasteur Toxoid Vaccines Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. Sanofi Pasteur Toxoid Vaccines Product Portfolio Table 96. Sanofi Pasteur Recent Development Table 97. Panacea Biotec Company Information Table 98. Panacea Biotec Business Overview Table 99. Panacea Biotec Toxoid Vaccines Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. Panacea Biotec Toxoid Vaccines Product Portfolio Table 101. Panacea Biotec Recent Development Table 102. Emergent Biosolutions Company Information Table 103. Emergent Biosolutions Business Overview Table 104. Emergent Biosolutions Toxoid Vaccines Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. Emergent Biosolutions Toxoid Vaccines Product Portfolio Table 106. Emergent Biosolutions Recent Development Table 107. Bharat Biotech Company Information Table 108. Bharat Biotech Business Overview Table 109. Bharat Biotech Toxoid Vaccines Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 110. Bharat Biotech Toxoid Vaccines Product Portfolio Table 111. Bharat Biotech Recent Development Table 112. Bausch Health Company Information Table 113. Bausch Health Business Overview Table 114. Bausch Health Toxoid Vaccines Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 115. Bausch Health Toxoid Vaccines Product Portfolio Table 116. Bausch Health Recent Development Table 117. Astellas Pharma Company Information Table 118. Astellas Pharma Business Overview Table 119. Astellas Pharma Toxoid Vaccines Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 120. Astellas Pharma Toxoid Vaccines Product Portfolio Table 121. Astellas Pharma Recent Development Table 122. Key Raw Materials Table 123. Raw Materials Key Suppliers Table 124. Toxoid Vaccines Distributors List Table 125. Toxoid Vaccines Customers List Table 126. Research Programs/Design for This Report Table 127. Authors List of This Report Table 128. Secondary Sources Table 129. Primary Sources List of Figures Figure 1. Toxoid Vaccines Product Image Figure 2. Global Toxoid Vaccines Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Toxoid Vaccines Market Size (2021-2032) & (US$ Million) Figure 4. Global Toxoid Vaccines Sales (2021-2032) & (k units) Figure 5. Global Toxoid Vaccines Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Toxoid Vaccines Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Tetanus Image Figure 9. Monovalent Tetanus Toxoid (TT) Image Figure 10. Pertussis (DTaP) Image Figure 11. Diphtheria and Tetanus (DT) Image Figure 12. Diphtheria Image Figure 13. Global Toxoid Vaccines Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global Toxoid Vaccines Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Toxoid Vaccines Sales Market Share by Type (2021-2032) Figure 16. Global Toxoid Vaccines Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 17. Global Toxoid Vaccines Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Toxoid Vaccines Revenue Market Share by Type (2021-2032) Figure 19. Government Organizations Image Figure 20. Hospitals And Clinics Image Figure 21. Research Image Figure 22. Others Image Figure 23. Global Toxoid Vaccines Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 24. Global Toxoid Vaccines Sales Market Share 2021 VS 2025 VS 2032 Figure 25. Global Toxoid Vaccines Sales Market Share by Application (2021-2032) Figure 26. Global Toxoid Vaccines Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 27. Global Toxoid Vaccines Revenue Market Share 2021 VS 2025 VS 2032 Figure 28. Global Toxoid Vaccines Revenue Market Share by Application (2021-2032) Figure 29. North America Toxoid Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 30. North America Toxoid Vaccines Sales Market Share by Country (2021-2032) Figure 31. U.S. Toxoid Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 32. Canada Toxoid Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 33. Mexico Toxoid Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 34. Europe Toxoid Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 35. Europe Toxoid Vaccines Sales Market Share by Country (2021-2032) Figure 36. Germany Toxoid Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 37. France Toxoid Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 38. U.K. Toxoid Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 39. Italy Toxoid Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 40. Netherlands Toxoid Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 41. Asia Pacific Toxoid Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 42. Asia Pacific Toxoid Vaccines Sales Market Share by Country (2021-2032) Figure 43. China Toxoid Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 44. Japan Toxoid Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 45. South Korea Toxoid Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 46. Southeast Asia Toxoid Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 47. India Toxoid Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 48. Australia Toxoid Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 49. South America, Middle East and Africa Toxoid Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 50. South America, Middle East and Africa Toxoid Vaccines Sales Market Share by Country (2021-2032) Figure 51. Brazil Toxoid Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 52. South Africa Toxoid Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 53. Saudi Arabia Toxoid Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 54. Turkey Toxoid Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 55. Argentina Toxoid Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 56. UAE Toxoid Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 57. Egypt Toxoid Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 58. Chile Toxoid Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 59. Global Toxoid Vaccines Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Global Toxoid Vaccines Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 61. North America Toxoid Vaccines Revenue (2021-2032) & (US$ Million) Figure 62. North America Toxoid Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Europe Toxoid Vaccines Revenue (2021-2032) & (US$ Million) Figure 64. Europe Toxoid Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Asia-Pacific Toxoid Vaccines Revenue (2021-2032) & (US$ Million) Figure 66. Asia-Pacific Toxoid Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. South America, Middle East and Africa Toxoid Vaccines Revenue (2021-2032) & (US$ Million) Figure 68. South America, Middle East and Africa Toxoid Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. Toxoid Vaccines Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Toxoid Vaccines Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Tetanus
  • Monovalent Tetanus Toxoid (TT)
  • Pertussis (DTaP)
  • Diphtheria and Tetanus (DT)
  • Diphtheria
Applications
  • Government Organizations
  • Hospitals And Clinics
  • Research
  • Others
Companies covered
  • Shenzhen Kangtai Biological Products
  • Merck
  • Pfizer
  • GlaxoSmithKline
  • AstraZeneca
  • Sanofi Pasteur
  • Panacea Biotec
  • Emergent Biosolutions
  • Bharat Biotech
  • Bausch Health
  • Astellas Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Toxoid Vaccines Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Toxoid Vaccines Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Toxoid Vaccines Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Toxoid Vaccines Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Toxoid Vaccines Market Dynamics
  1. 2.1 Toxoid Vaccines Industry Trends
  2. 2.2 Toxoid Vaccines Industry Drivers
  3. 2.3 Toxoid Vaccines Industry Opportunities and Challenges
  4. 2.4 Toxoid Vaccines Industry Restraints
3 Toxoid Vaccines Market by Manufacturers
  1. 3.1 Global Toxoid Vaccines Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Toxoid Vaccines Sales by Manufacturers (2021-2026)
  3. 3.3 Global Toxoid Vaccines Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Toxoid Vaccines Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Toxoid Vaccines Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Toxoid Vaccines Manufacturers, Product Type & Application
  7. 3.7 Global Toxoid Vaccines Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Toxoid Vaccines Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Toxoid Vaccines Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Toxoid Vaccines Tier 1, Tier 2, and Tier 3
4 Toxoid Vaccines Market by Type
  1. 4.1 Toxoid Vaccines Type Introduction
  2. 4.1.1 Tetanus
  3. 4.1.2 Monovalent Tetanus Toxoid (TT)
  4. 4.1.3 Pertussis (DTaP)
  5. 4.1.4 Diphtheria and Tetanus (DT)
  6. 4.1.5 Diphtheria
  7. 4.2 Global Toxoid Vaccines Sales by Type
  8. 4.2.1 Global Toxoid Vaccines Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Toxoid Vaccines Sales by Type (2021-2032)
  10. 4.2.3 Global Toxoid Vaccines Sales Market Share by Type (2021-2032)
  11. 4.3 Global Toxoid Vaccines Revenue by Type
  12. 4.3.1 Global Toxoid Vaccines Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Toxoid Vaccines Revenue by Type (2021-2032)
  14. 4.3.3 Global Toxoid Vaccines Revenue Market Share by Type (2021-2032)
5 Toxoid Vaccines Market by Application
  1. 5.1 Toxoid Vaccines Application Introduction
  2. 5.1.1 Government Organizations
  3. 5.1.2 Hospitals And Clinics
  4. 5.1.3 Research
  5. 5.1.4 Others
  6. 5.2 Global Toxoid Vaccines Sales by Application
  7. 5.2.1 Global Toxoid Vaccines Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Toxoid Vaccines Sales by Application (2021-2032)
  9. 5.2.3 Global Toxoid Vaccines Sales Market Share by Application (2021-2032)
  10. 5.3 Global Toxoid Vaccines Revenue by Application
  11. 5.3.1 Global Toxoid Vaccines Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Toxoid Vaccines Revenue by Application (2021-2032)
  13. 5.3.3 Global Toxoid Vaccines Revenue Market Share by Application (2021-2032)
6 Global Toxoid Vaccines Sales by Region
  1. 6.1 Global Toxoid Vaccines Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Toxoid Vaccines Sales by Region (2021-2032)
  3. 6.2.1 Global Toxoid Vaccines Sales by Region (2021-2026)
  4. 6.2.2 Global Toxoid Vaccines Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Toxoid Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Toxoid Vaccines Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Toxoid Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Toxoid Vaccines Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Toxoid Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Toxoid Vaccines Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Toxoid Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Toxoid Vaccines Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Toxoid Vaccines Revenue by Region
  1. 7.1 Global Toxoid Vaccines Revenue by Region
  2. 7.1.1 Global Toxoid Vaccines Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Toxoid Vaccines Revenue by Region (2021-2026)
  4. 7.1.3 Global Toxoid Vaccines Revenue by Region (2027-2032)
  5. 7.1.4 Global Toxoid Vaccines Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Toxoid Vaccines Revenue (2021-2032)
  8. 7.2.2 North America Toxoid Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Toxoid Vaccines Revenue (2021-2032)
  11. 7.3.2 Europe Toxoid Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Toxoid Vaccines Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Toxoid Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Toxoid Vaccines Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Toxoid Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Shenzhen Kangtai Biological Products
  2. 8.1.1 Shenzhen Kangtai Biological Products Company Information
  3. 8.1.2 Shenzhen Kangtai Biological Products Business Overview
  4. 8.1.3 Shenzhen Kangtai Biological Products Toxoid Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Shenzhen Kangtai Biological Products Toxoid Vaccines Product Portfolio
  6. 8.1.5 Shenzhen Kangtai Biological Products Recent Developments
  7. 8.2 Merck
  8. 8.2.1 Merck Company Information
  9. 8.2.2 Merck Business Overview
  10. 8.2.3 Merck Toxoid Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Merck Toxoid Vaccines Product Portfolio
  12. 8.2.5 Merck Recent Developments
  13. 8.3 Pfizer
  14. 8.3.1 Pfizer Company Information
  15. 8.3.2 Pfizer Business Overview
  16. 8.3.3 Pfizer Toxoid Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Pfizer Toxoid Vaccines Product Portfolio
  18. 8.3.5 Pfizer Recent Developments
  19. 8.4 GlaxoSmithKline
  20. 8.4.1 GlaxoSmithKline Company Information
  21. 8.4.2 GlaxoSmithKline Business Overview
  22. 8.4.3 GlaxoSmithKline Toxoid Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 GlaxoSmithKline Toxoid Vaccines Product Portfolio
  24. 8.4.5 GlaxoSmithKline Recent Developments
  25. 8.5 AstraZeneca
  26. 8.5.1 AstraZeneca Company Information
  27. 8.5.2 AstraZeneca Business Overview
  28. 8.5.3 AstraZeneca Toxoid Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 AstraZeneca Toxoid Vaccines Product Portfolio
  30. 8.5.5 AstraZeneca Recent Developments
  31. 8.6 Sanofi Pasteur
  32. 8.6.1 Sanofi Pasteur Company Information
  33. 8.6.2 Sanofi Pasteur Business Overview
  34. 8.6.3 Sanofi Pasteur Toxoid Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Sanofi Pasteur Toxoid Vaccines Product Portfolio
  36. 8.6.5 Sanofi Pasteur Recent Developments
  37. 8.7 Panacea Biotec
  38. 8.7.1 Panacea Biotec Company Information
  39. 8.7.2 Panacea Biotec Business Overview
  40. 8.7.3 Panacea Biotec Toxoid Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Panacea Biotec Toxoid Vaccines Product Portfolio
  42. 8.7.5 Panacea Biotec Recent Developments
  43. 8.8 Emergent Biosolutions
  44. 8.8.1 Emergent Biosolutions Company Information
  45. 8.8.2 Emergent Biosolutions Business Overview
  46. 8.8.3 Emergent Biosolutions Toxoid Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Emergent Biosolutions Toxoid Vaccines Product Portfolio
  48. 8.8.5 Emergent Biosolutions Recent Developments
  49. 8.9 Bharat Biotech
  50. 8.9.1 Bharat Biotech Company Information
  51. 8.9.2 Bharat Biotech Business Overview
  52. 8.9.3 Bharat Biotech Toxoid Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Bharat Biotech Toxoid Vaccines Product Portfolio
  54. 8.9.5 Bharat Biotech Recent Developments
  55. 8.10 Bausch Health
  56. 8.10.1 Bausch Health Company Information
  57. 8.10.2 Bausch Health Business Overview
  58. 8.10.3 Bausch Health Toxoid Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Bausch Health Toxoid Vaccines Product Portfolio
  60. 8.10.5 Bausch Health Recent Developments
  61. 8.11 Astellas Pharma
  62. 8.11.1 Astellas Pharma Company Information
  63. 8.11.2 Astellas Pharma Business Overview
  64. 8.11.3 Astellas Pharma Toxoid Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Astellas Pharma Toxoid Vaccines Product Portfolio
  66. 8.11.5 Astellas Pharma Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Toxoid Vaccines Value Chain Analysis
  2. 9.1.1 Toxoid Vaccines Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Toxoid Vaccines Production Mode & Process
  6. 9.2 Toxoid Vaccines Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Toxoid Vaccines Distributors
  9. 9.2.3 Toxoid Vaccines Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst